Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

COVID-19 vaccination may offer less effective and shorter-lasting protection for some cancer patients

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalization and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

7 Jun 2022

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

6 Jun 2022

Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

6 Jun 2022

Children with leukemia have higher survival than adolescents and young adults with the same cancer

Children (0-14 years) diagnosed with leukemia have benefited from decades of research to improve outcomes, and their five-year survival has increased more than that of adolescents (15-19 years) and young adults (20-24 years), suggests new research published in The Lancet Child and Adolescent Health.

6 Jun 2022

Addressing the ‘trust factor’: South Carolina researchers tackle health disparities using genetics

Quenton Tompkins' family tree is deeply rooted in rural McCormick County, South Carolina.

6 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

New study uncovers the impact of genetic mutations on lifelong blood cell production

New research has uncovered how genetic mutations hijack the production of blood cells in different periods of life.

1 Jun 2022

New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic leukemia with rearrangements of the mixed lineage leukemia gene, or MLL B-ALL.

1 Jun 2022

Aging does not influence liver renewal, research shows

The liver has a unique ability to regenerate after damage. However, it was unknown whether this ability decreases as we age.

31 May 2022

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.

26 May 2022

Novel mechanism to turn on cancer-killing T cells identified

Over the past decade, researchers have made great strides in the development and administration of cancer immunotherapies, which use the body's own immune system to treat disease.

25 May 2022

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

24 May 2022

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

Penn Medicine and Children's Hospital of Philadelphia, who together pioneered the research and development of the world's first personalized cellular therapy for cancer - also known as CAR T cell therapy - have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica.

23 May 2022

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.

23 May 2022

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.

18 May 2022

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.

13 May 2022

Unique binding property may explain the ability of delta variant to spread more rapidly

Unlike other SARS-CoV-2 variants, the Delta variant can attach to copies of itself, forming larger aggregations, or clumps, of viral particles, suggests a study by scientists at the National Institutes of Health.

11 May 2022

New classification by ESMO to guide research on treatment de-escalation in oncology

ESMO, the leading professional organization for medical oncology, has developed a new evidence-based classification to guide research and interpretation of data on treatment de-escalation in oncology.

11 May 2022

Leukemia News and Research

Further Reading

COVID-19 vaccination may offer less effective and shorter-lasting protection for some cancer patients

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Children with leukemia have higher survival than adolescents and young adults with the same cancer

Addressing the ‘trust factor’: South Carolina researchers tackle health disparities using genetics

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

New study uncovers the impact of genetic mutations on lifelong blood cell production

New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Aging does not influence liver renewal, research shows

Risk factors for COVID-19 in patients with hematological malignancies

HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

Novel mechanism to turn on cancer-killing T cells identified

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Unique binding property may explain the ability of delta variant to spread more rapidly

New classification by ESMO to guide research on treatment de-escalation in oncology

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News